Biotech Values

[ghmm]

WPI:

A couple of things from the call:
. The agreement doesn't prohibit Watson from pursuing Biosimilars for Amgen products and they have the right of first refusal should Amgen choose to come out with an Authorized Generic.
. Global arrangement, they expect products in Europe before the US (but also mentioned other countries in passing such as Brasil).
. They were looking for partners for the past 15 months or so. Said a lot of companies had the products in their portfolio some were limited financially (50%) others by scientific or manufacturing capability.
. There is a finite number of products associated with the deal.
. Think some areas may get approved on single study (though this was in response to multiple indications for a single drug).
. Don't rule out doing other deals but further down the road.
. Amgen is doing all the manufacturing.